Sector News

Daiichi Sankyo, Inc. reorganizes U.S. Commercial Operations to support specialty pipeline

October 20, 2015
Life sciences

Daiichi Sankyo, Inc. announced today that it will reorganize its U.S. Commercial organization as it begins to transition from a maturing primary care product portfolio to a differentiated specialty portfolio that will include areas such as cardiovascular, pain management and oncology.

“As we face the loss of exclusivity in the coming year of our largest product, we also look ahead to great opportunities with our emerging portfolio in cardiology, oncology, fibromyalgia and pain relief,” said Ken Keller, President, U.S. Commercial, Daiichi Sankyo, Inc. “This calls for us to restructure our organization into a smaller, highly targeted and efficient operating model, with a greater emphasis on customer-facing roles.”

As part of the reorganization, the Company will reduce expenses, including a reduction in headcount, from its U.S. Commercial operations. The Company expects to eliminate 1,000 to 1,200 positions across the U.S. Commercial function, through voluntary and involuntary displacements as well as eliminating open positions. The eliminated jobs will come from the U.S. Commercial Home Office, located in Parsippany, New Jersey, as well as field-based sales and other positions throughout the country. This reorganization is not focused on U.S.-based R&D functions, which have staff concentrated in Edison, NJ, or its packaging plant in Bethlehem, PA.

“Daiichi Sankyo recognizes the macro changes occurring in the U.S. healthcare system that place a greater emphasis on managing the needs of patients with more complex healthcare needs. As a specialty company, we will be positioned to meet those needs and invest in advancing technologies that will make a significant difference in patient lives,” said Keller. “While this initiative will place us on the path toward long-term success, it does require us to make some difficult decisions. We are grateful for the contributions of all of our employees and are committed to making this process as easy and streamlined as possible for them through outplacement services and other support.”

Source: Daiichi Sankyo

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”